KNApSAcK Metabolite C00001003
Metabolite
KNApSAcK Entry
| id | C00001003 |
|---|---|
| Name | Silybin |
| CAS RN | 22888-70-6 |
| Standard InChI | InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1 |
| Standard InChI (Main Layer) | InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3 |
Cluster
| Phytochemical cluster | No. 14 |
|---|---|
| KCF-S cluster | No. 585 |
Link
ChEMBL
| By standard InChI | CHEMBL431701 |
|---|---|
| By standard InChI Main Layer | CHEMBL9509 CHEMBL431701 CHEMBL245121 CHEMBL592675 CHEMBL1401508 CHEMBL1551617 |
KEGG
| By LinkDB | C07610 |
|---|
CTD
| By CAS RN | C440975 |
|---|
Species
Summary
Plant class
| class name | count |
|---|---|
| asterids | 1 |
Family
| family name | count |
|---|---|
| Asteraceae | 1 |
List (1)
* NCBI
| KNApSAcK organism | *ID | *family | *plant class | *kingdom |
|---|---|---|---|---|
| Silybum marianum | 92921 | Asteraceae | asterids | Viridiplantae |
Human Protein / Gene in interaction
57 ChEMBL Protein in interactions
| accession | description | class description | compound | assay ID (# of activities) |
# of diseases
(OMIM / KEGG) |
|---|---|---|---|---|---|
| P33527 | Multidrug resistance-associated protein 1 | drugs | CHEMBL1401508 |
CHEMBL2076018
(1)
CHEMBL2076029
(1)
|
0 / 0 |
| P04637 | Cellular tumor antigen p53 | Transcription Factor | CHEMBL1401508 |
CHEMBL1613995
(1)
|
7 / 44 |
| Q9UIF8 | Bromodomain adjacent to zinc finger domain protein 2B | Unclassified protein | CHEMBL431701 |
CHEMBL1738312
(1)
|
0 / 0 |
| P04062 | Glucosylceramidase | Enzyme | CHEMBL431701 CHEMBL1401508 CHEMBL1551617 |
CHEMBL1613818
(3)
|
6 / 4 |
| P10253 | Lysosomal alpha-glucosidase | Hydrolase | CHEMBL1401508 |
CHEMBL1614076
(1)
|
1 / 1 |
| Q9Y2D0 | Carbonic anhydrase 5B, mitochondrial | Lyase | CHEMBL1401508 |
CHEMBL1227478
(1)
|
0 / 0 |
| P35218 | Carbonic anhydrase 5A, mitochondrial | Lyase | CHEMBL1401508 |
CHEMBL1227477
(1)
|
0 / 0 |
| P43166 | Carbonic anhydrase 7 | Lyase | CHEMBL1401508 |
CHEMBL1227480
(1)
|
0 / 0 |
| Q03181 | Peroxisome proliferator-activated receptor delta | NR1C2 | CHEMBL431701 |
CHEMBL1794524
(1)
CHEMBL1794552
(1)
|
0 / 0 |
| Q8N1Q1 | Carbonic anhydrase 13 | Lyase | CHEMBL1401508 |
CHEMBL1227626
(1)
|
0 / 0 |
| P02545 | Prelamin-A/C | Unclassified protein | CHEMBL431701 |
CHEMBL1614544
(1)
|
11 / 10 |
| P16473 | Thyrotropin receptor | Glycohormone receptor | CHEMBL431701 |
CHEMBL1614281
(1)
CHEMBL1614361
(1)
|
3 / 2 |
| P10828 | Thyroid hormone receptor beta | NR1A2 | CHEMBL431701 |
CHEMBL1794399
(1)
|
3 / 1 |
| P19793 | Retinoic acid receptor RXR-alpha | NR2B1 | CHEMBL431701 |
CHEMBL1794371
(1)
|
0 / 0 |
| P00918 | Carbonic anhydrase 2 | Lyase | CHEMBL1401508 |
CHEMBL1227474
(1)
|
1 / 2 |
| P08183 | Multidrug resistance protein 1 | drug | CHEMBL1401508 |
CHEMBL2077116
(1)
CHEMBL2075514
(1)
CHEMBL2077294 (1) CHEMBL2077296 (1) |
1 / 0 |
| P11712 | Cytochrome P450 2C9 | Cytochrome P450 2C9 | CHEMBL592675 CHEMBL1401508 CHEMBL1551617 |
CHEMBL1614027
(1)
CHEMBL1743408
(2)
CHEMBL2320747 (2) |
0 / 1 |
| P11473 | Vitamin D3 receptor | NR1I1 | CHEMBL431701 |
CHEMBL1794311
(1)
|
2 / 3 |
| P23280 | Carbonic anhydrase 6 | Lyase | CHEMBL1401508 |
CHEMBL1227479
(1)
|
0 / 0 |
| Q9ULX7 | Carbonic anhydrase 14 | Lyase | CHEMBL1401508 |
CHEMBL1227627
(1)
|
0 / 0 |
| P00352 | Retinal dehydrogenase 1 | Enzyme | CHEMBL431701 CHEMBL1551617 |
CHEMBL1614458
(2)
|
0 / 0 |
| P17405 | Sphingomyelin phosphodiesterase | Enzyme | CHEMBL1401508 |
CHEMBL1794495
(1)
|
2 / 2 |
| O43570 | Carbonic anhydrase 12 | Lyase | CHEMBL1401508 |
CHEMBL1227625
(1)
|
1 / 2 |
| Q16665 | Hypoxia-inducible factor 1-alpha | Transcription Factor | CHEMBL1401508 |
CHEMBL1614456
(1)
CHEMBL1613803
(1)
|
0 / 0 |
| P84022 | Mothers against decapentaplegic homolog 3 | Unclassified protein | CHEMBL431701 |
CHEMBL1794584
(1)
|
2 / 0 |
| O75496 | Geminin | Unclassified protein | CHEMBL431701 CHEMBL245121 CHEMBL1401508 |
CHEMBL2114843
(2)
CHEMBL2114780
(1)
|
0 / 0 |
| P10145 | Interleukin-8 | Secreted protein | CHEMBL431701 |
CHEMBL2114835
(1)
|
0 / 0 |
| P00915 | Carbonic anhydrase 1 | Lyase | CHEMBL1401508 |
CHEMBL1227473
(1)
|
0 / 0 |
| P63092 | Guanine nucleotide-binding protein G(s) subunit alpha isoforms short | Other membrane protein | CHEMBL431701 CHEMBL245121 CHEMBL1401508 |
CHEMBL2114817
(3)
|
7 / 3 |
| Q9Y253 | DNA polymerase eta | Enzyme | CHEMBL245121 |
CHEMBL1794569
(1)
|
1 / 1 |
| P37231 | Peroxisome proliferator-activated receptor gamma | NR1C3 | CHEMBL431701 |
CHEMBL1794510
(1)
|
5 / 3 |
| P18054 | Arachidonate 12-lipoxygenase, 12S-type | Enzyme | CHEMBL1551617 |
CHEMBL1614252
(1)
|
2 / 0 |
| Q96RI1 | Bile acid receptor | NR1H4 | CHEMBL431701 |
CHEMBL1794415
(1)
|
0 / 0 |
| Q16790 | Carbonic anhydrase 9 | Lyase | CHEMBL1401508 |
CHEMBL1228226
(1)
|
0 / 1 |
| Q99714 | 3-hydroxyacyl-CoA dehydrogenase type-2 | Enzyme | CHEMBL431701 CHEMBL1551617 |
CHEMBL1613910
(2)
CHEMBL1614227
(2)
|
3 / 3 |
| Q9UNQ0 | ATP-binding cassette sub-family G member 2 | ATP binding cassette | CHEMBL1401508 |
CHEMBL2076816
(1)
CHEMBL2076817
(1)
CHEMBL2076831 (1) CHEMBL2076832 (1) |
2 / 0 |
| Q92887 | Canalicular multispecific organic anion transporter 1 | Unclassified protein | CHEMBL9509 |
CHEMBL1006005
(1)
|
1 / 1 |
| P15428 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)] | Enzyme | CHEMBL1401508 CHEMBL1551617 |
CHEMBL1614038
(2)
|
2 / 2 |
| P51449 | Nuclear receptor ROR-gamma | Nuclear hormone receptor subfamily 1 group F member 3 | CHEMBL431701 |
CHEMBL2114842
(1)
|
0 / 0 |
| P03372 | Estrogen receptor | NR3A1 | CHEMBL431701 |
CHEMBL1794364
(1)
|
1 / 1 |
| P16050 | Arachidonate 15-lipoxygenase | Enzyme | CHEMBL431701 CHEMBL1401508 CHEMBL1551617 |
CHEMBL1614240
(3)
|
0 / 0 |
| P33261 | Cytochrome P450 2C19 | Cytochrome P450 2C19 | CHEMBL1551617 |
CHEMBL1613777
(1)
|
1 / 1 |
| P08684 | Cytochrome P450 3A4 | Cytochrome P450 3A4 | CHEMBL431701 CHEMBL1401508 CHEMBL1551617 |
CHEMBL1614108
(3)
CHEMBL1613886
(3)
CHEMBL1743435 (2) CHEMBL1743466 (2) |
0 / 1 |
| Q9UNA4 | DNA polymerase iota | Enzyme | CHEMBL431701 CHEMBL245121 |
CHEMBL1794483
(2)
|
0 / 0 |
| P27695 | DNA-(apurinic or apyrimidinic site) lyase | Enzyme | CHEMBL1551617 |
CHEMBL1614211
(1)
|
0 / 0 |
| P10636 | Microtubule-associated protein tau | Unclassified protein | CHEMBL1401508 CHEMBL1551617 |
CHEMBL1614421
(2)
CHEMBL1614502
(1)
|
4 / 3 |
| Q16236 | Nuclear factor erythroid 2-related factor 2 | Unclassified protein | CHEMBL431701 |
CHEMBL2114890
(1)
|
0 / 0 |
| P10275 | Androgen receptor | NR3C4 | CHEMBL431701 |
CHEMBL1794321
(1)
|
3 / 4 |
| P07451 | Carbonic anhydrase 3 | Lyase | CHEMBL1401508 |
CHEMBL1227475
(1)
|
0 / 0 |
| P22748 | Carbonic anhydrase 4 | Lyase | CHEMBL1401508 |
CHEMBL1227476
(1)
|
1 / 1 |
| Q9UBT6 | DNA polymerase kappa | Enzyme | CHEMBL1551617 |
CHEMBL1794536
(1)
|
0 / 0 |
| B2RXH2 | Lysine-specific demethylase 4E | Enzyme | CHEMBL1551617 |
CHEMBL1613914
(1)
|
0 / 0 |
| Q96KQ7 | Histone-lysine N-methyltransferase EHMT2 | Enzyme | CHEMBL245121 CHEMBL1401508 |
CHEMBL1738442
(2)
|
0 / 0 |
| Q9NUW8 | Tyrosyl-DNA phosphodiesterase 1 | Enzyme | CHEMBL431701 |
CHEMBL1614364
(1)
|
1 / 1 |
| O00255 | Menin | Unclassified protein | CHEMBL1551617 |
CHEMBL1614531
(1)
|
2 / 5 |
| Q03164 | Histone-lysine N-methyltransferase 2A | Enzyme | CHEMBL1551617 |
CHEMBL1614531
(1)
|
1 / 3 |
| O94925 | Glutaminase kidney isoform, mitochondrial | Enzyme | CHEMBL431701 |
CHEMBL2114738
(1)
|
0 / 0 |
CTD interaction (60)
| compound | gene | gene name | gene description | interaction | interaction type | form |
reference
pmid |
|---|---|---|---|---|---|---|---|
| C440975 | 8644 |
AKR1C3
DD3 DDX HA1753 HAKRB HAKRe HSD17B5 PGFS hluPGFS |
aldo-keto reductase family 1, member C3 (EC:1.3.1.20 1.1.1.188 1.1.1.239 1.1.1.64 1.1.1.112 1.1.1.357) | silybin results in decreased activity of AKR1C3 protein |
decreases activity
|
protein |
19007764
|
| C440975 | 472 |
ATM
AT1 ATA ATC ATD ATDC ATE TEL1 TELO1 |
ataxia telangiectasia mutated (EC:2.7.11.1) | silybin results in increased phosphorylation of and results in increased activity of ATM protein |
increases activity
/ increases phosphorylation |
protein |
16777994
|
| C440975 | 581 |
BAX
BCL2L4 |
BCL2-associated X protein | silybin inhibits the reaction [Mitomycin affects the localization of BAX protein] |
affects localization
/ decreases reaction |
protein |
19834285
|
| C440975 | 596 |
BCL2
Bcl-2 PPP1R50 |
B-cell CLL/lymphoma 2 | silybin inhibits the reaction [Mitomycin affects the expression of BCL2] |
affects expression
/ decreases reaction |
19834285
|
|
| C440975 | 637 |
BID
FP497 |
BH3 interacting domain death agonist | benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [silybin results in increased cleavage of BID protein] |
decreases reaction
/ increases cleavage |
protein |
16777994
|
| C440975 | 637 |
BID
FP497 |
BH3 interacting domain death agonist | Caffeine inhibits the reaction [silybin results in increased cleavage of BID protein] |
decreases reaction
/ increases cleavage |
protein |
16777994
|
| C440975 | 637 |
BID
FP497 |
BH3 interacting domain death agonist | pifithrin inhibits the reaction [silybin results in increased cleavage of BID protein] |
decreases reaction
/ increases cleavage |
protein |
16777994
|
| C440975 | 637 |
BID
FP497 |
BH3 interacting domain death agonist | silybin affects the localization of BID protein modified form |
affects localization
|
protein |
16777994
|
| C440975 | 637 |
BID
FP497 |
BH3 interacting domain death agonist | silybin results in increased cleavage of BID protein |
increases cleavage
|
protein |
16777994
|
| C440975 | 835 |
CASP2
CASP-2 ICH1 NEDD-2 NEDD2 PPP1R57 |
caspase 2, apoptosis-related cysteine peptidase (EC:3.4.22.55) | benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP2 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
16777994
|
| C440975 | 835 |
CASP2
CASP-2 ICH1 NEDD-2 NEDD2 PPP1R57 |
caspase 2, apoptosis-related cysteine peptidase (EC:3.4.22.55) | Caffeine inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP2 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
16777994
|
| C440975 | 835 |
CASP2
CASP-2 ICH1 NEDD-2 NEDD2 PPP1R57 |
caspase 2, apoptosis-related cysteine peptidase (EC:3.4.22.55) | pifithrin inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP2 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
16777994
|
| C440975 | 835 |
CASP2
CASP-2 ICH1 NEDD-2 NEDD2 PPP1R57 |
caspase 2, apoptosis-related cysteine peptidase (EC:3.4.22.55) | silybin results in increased cleavage of and results in increased activity of CASP2 protein |
increases activity
/ increases cleavage |
protein |
16777994
|
| C440975 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP3 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
16777994
|
| C440975 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | Caffeine inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP3 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
16777994
|
| C440975 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | pifithrin inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP3 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
16777994
|
| C440975 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | silybin results in increased cleavage of and results in increased activity of CASP3 protein |
increases activity
/ increases cleavage |
protein |
16777994
|
| C440975 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP8 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
16777994
|
| C440975 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | pifithrin inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP8 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
16777994
|
| C440975 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | silybin results in increased cleavage of and results in increased activity of CASP8 protein |
increases activity
/ increases cleavage |
protein |
16777994
|
| C440975 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP9 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
16777994
|
| C440975 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | Caffeine inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP9 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
16777994
|
| C440975 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | pifithrin inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP9 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
16777994
|
| C440975 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | silybin results in increased cleavage of and results in increased activity of CASP9 protein |
increases activity
/ increases cleavage |
protein |
16777994
|
| C440975 | 1026 |
CDKN1A
CAP20 CDKN1 CIP1 MDA-6 P21 SDI1 WAF1 p21CIP1 |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) | benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [silybin results in increased cleavage of CDKN1A protein] |
decreases reaction
/ increases cleavage |
protein |
16777994
|
| C440975 | 1026 |
CDKN1A
CAP20 CDKN1 CIP1 MDA-6 P21 SDI1 WAF1 p21CIP1 |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) | silybin results in increased cleavage of CDKN1A protein |
increases cleavage
|
protein |
16777994
|
| C440975 | 11200 |
CHEK2
CDS1 CHK2 HuCds1 LFS2 PP1425 RAD53 hCds1 |
checkpoint kinase 2 (EC:2.7.11.1) | Caffeine inhibits the reaction [silybin results in increased phosphorylation of CHEK2 protein] |
decreases reaction
/ increases phosphorylation |
protein |
16777994
|
| C440975 | 11200 |
CHEK2
CDS1 CHK2 HuCds1 LFS2 PP1425 RAD53 hCds1 |
checkpoint kinase 2 (EC:2.7.11.1) | silybin results in increased phosphorylation of CHEK2 protein |
increases phosphorylation
|
protein |
16777994
|
| C440975 | 1559 |
CYP2C9
CPC9 CYP2C CYP2C10 CYPIIC9 P450IIC9 |
cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | silybin results in decreased activity of CYP2C9 protein |
decreases activity
|
protein |
15155549
|
| C440975 | 1576 |
CYP3A4
CP33 CP34 CYP3A CYP3A3 CYPIIIA3 CYPIIIA4 HLP NF-25 P450C3 P450PCN1 |
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | silybin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone] |
decreases reaction
/ increases hydroxylation |
protein |
15155549
|
| C440975 | 1576 |
CYP3A4
CP33 CP34 CYP3A CYP3A3 CYPIIIA3 CYPIIIA4 HLP NF-25 P450C3 P450PCN1 |
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | silybin results in decreased activity of CYP3A4 protein |
decreases activity
|
protein |
15155549
|
| C440975 | 1649 |
DDIT3
CEBPZ CHOP CHOP-10 CHOP10 GADD153 |
DNA-damage-inducible transcript 3 | DDIT3 affects the reaction [silybin results in increased expression of TNFRSF10B] |
affects reaction
/ increases expression |
19939880
|
|
| C440975 | 2099 |
ESR1
ER ESR ESRA ESTRR Era NR3A1 |
estrogen receptor 1 | silybin results in increased activity of [ESR1 protein binds to ESR2 protein] |
affects binding
/ increases activity |
protein |
16076518
|
| C440975 | 2100 |
ESR2
ER-BETA ESR-BETA ESRB ESTRB Erb NR3A2 |
estrogen receptor 2 (ER beta) | silybin results in increased activity of [ESR1 protein binds to ESR2 protein] |
affects binding
/ increases activity |
protein |
16076518
|
| C440975 | 3014 |
H2AFX
H2A.X H2A/X H2AX |
H2A histone family, member X | Caffeine inhibits the reaction [silybin results in increased phosphorylation of H2AFX protein] |
decreases reaction
/ increases phosphorylation |
protein |
16777994
|
| C440975 | 3014 |
H2AFX
H2A.X H2A/X H2AX |
H2A histone family, member X | silybin results in increased phosphorylation of H2AFX protein |
increases phosphorylation
|
protein |
16777994
|
| C440975 | 5599 |
MAPK8
JNK JNK-46 JNK1 JNK1A2 JNK21B1/2 PRKM8 SAPK1 SAPK1c |
mitogen-activated protein kinase 8 (EC:2.7.11.24) | anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [silybin results in increased phosphorylation of MAPK8 protein] |
decreases reaction
/ increases phosphorylation |
protein |
16777994
|
| C440975 | 5599 |
MAPK8
JNK JNK-46 JNK1 JNK1A2 JNK21B1/2 PRKM8 SAPK1 SAPK1c |
mitogen-activated protein kinase 8 (EC:2.7.11.24) | pifithrin inhibits the reaction [silybin results in increased phosphorylation of MAPK8 protein] |
decreases reaction
/ increases phosphorylation |
protein |
16777994
|
| C440975 | 5599 |
MAPK8
JNK JNK-46 JNK1 JNK1A2 JNK21B1/2 PRKM8 SAPK1 SAPK1c |
mitogen-activated protein kinase 8 (EC:2.7.11.24) | silybin results in increased phosphorylation of MAPK8 protein |
increases phosphorylation
|
protein |
16777994
|
| C440975 | 5601 |
MAPK9
JNK-55 JNK2 JNK2A JNK2ALPHA JNK2B JNK2BETA PRKM9 SAPK SAPK1a p54a p54aSAPK |
mitogen-activated protein kinase 9 (EC:2.7.11.24) | anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [silybin results in increased phosphorylation of MAPK9 protein] |
decreases reaction
/ increases phosphorylation |
protein |
16777994
|
| C440975 | 5601 |
MAPK9
JNK-55 JNK2 JNK2A JNK2ALPHA JNK2B JNK2BETA PRKM9 SAPK SAPK1a p54a p54aSAPK |
mitogen-activated protein kinase 9 (EC:2.7.11.24) | pifithrin inhibits the reaction [silybin results in increased phosphorylation of MAPK9 protein] |
decreases reaction
/ increases phosphorylation |
protein |
16777994
|
| C440975 | 5601 |
MAPK9
JNK-55 JNK2 JNK2A JNK2ALPHA JNK2B JNK2BETA PRKM9 SAPK SAPK1a p54a p54aSAPK |
mitogen-activated protein kinase 9 (EC:2.7.11.24) | silybin results in increased phosphorylation of MAPK9 protein |
increases phosphorylation
|
protein |
16777994
|
| C440975 | 4255 |
MGMT
|
O-6-methylguanine-DNA methyltransferase (EC:2.1.1.63) | silybin results in increased expression of and results in increased activity of MGMT protein |
increases activity
/ increases expression |
protein |
16950796
|
| C440975 | 110357 | silybin results in increased expression of MOD2 mRNA |
increases expression
|
mRNA |
16442130
|
||
| C440975 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | pifithrin inhibits the reaction [silybin results in increased cleavage of PARP1 protein] |
decreases reaction
/ increases cleavage |
protein |
16777994
|
| C440975 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | silybin results in increased cleavage of and results in increased activity of PARP1 protein |
increases activity
/ increases cleavage |
protein |
16777994
|
| C440975 | 6566 |
SLC16A1
HHF7 MCT MCT1 |
solute carrier family 16 (monocarboxylate transporter), member 1 | silybin inhibits the reaction [SLC16A1 protein results in increased uptake of Benzoic Acid] |
decreases reaction
/ increases uptake |
protein |
17976262
|
| C440975 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | DDIT3 affects the reaction [silybin results in increased expression of TNFRSF10B] |
affects reaction
/ increases expression |
19939880
|
|
| C440975 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | silybin results in increased expression of TNFRSF10B |
increases expression
|
19939880
|
|
| C440975 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | Caffeine inhibits the reaction [silybin results in increased phosphorylation of TP53 protein] |
decreases reaction
/ increases phosphorylation |
protein |
16777994
|
| C440975 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | pifithrin inhibits the reaction [silybin results in increased phosphorylation of TP53 protein] |
decreases reaction
/ increases phosphorylation |
protein |
16777994
|
| C440975 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | silybin affects the localization of TP53 protein |
affects localization
|
protein |
16777994
|
| C440975 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | silybin inhibits the reaction [Mitomycin results in increased expression of TP53] |
decreases reaction
/ increases expression |
19834285
|
|
| C440975 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | silybin results in increased expression of TP53 protein |
increases expression
|
protein |
16777994
|
| C440975 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | silybin results in increased phosphorylation of TP53 protein |
increases phosphorylation
|
protein |
16777994
|
| C440975 | 54658 |
UGT1A1
BILIQTL1 GNT1 HUG-BR1 UDPGT UDPGT_1-1 UGT1 UGT1A |
UDP glucuronosyltransferase 1 family, polypeptide A1 (EC:2.4.1.17) | silybin inhibits the reaction [UGT1A1 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin] |
decreases reaction
/ increases glucuronidation |
protein |
15155549
|
| C440975 | 54578 |
UGT1A6
GNT1 HLUGP HLUGP1 UDPGT UDPGT_1-6 UGT1 UGT1A6S UGT1F |
UDP glucuronosyltransferase 1 family, polypeptide A6 (EC:2.4.1.17) | silybin inhibits the reaction [UGT1A6 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin] |
decreases reaction
/ increases glucuronidation |
protein |
15155549
|
| C440975 | 54600 |
UGT1A9
HLUGP4 LUGP4 UDPGT UDPGT_1-9 UGT-1I UGT1-09 UGT1-9 UGT1.9 UGT1AI UGT1I |
UDP glucuronosyltransferase 1 family, polypeptide A9 (EC:2.4.1.17) | silybin inhibits the reaction [UGT1A9 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin] |
decreases reaction
/ increases glucuronidation |
protein |
15155549
|
| C440975 | 7366 |
UGT2B15
HLUG4 UDPGT_2B8 UDPGT2B15 UDPGTH3 UGT2B8 |
UDP glucuronosyltransferase 2 family, polypeptide B15 (EC:2.4.1.17) | silybin inhibits the reaction [UGT2B15 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin] |
decreases reaction
/ increases glucuronidation |
protein |
15155549
|
| C440975 | 7364 |
UGT2B7
UDPGT_2B9 UDPGT2B7 UDPGTH2 UGT2B9 |
UDP glucuronosyltransferase 2 family, polypeptide B7 (EC:2.4.1.17) | silybin inhibits the reaction [UGT2B7 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin] |
decreases reaction
/ increases glucuronidation |
protein |
15155549
|
Related Disease
Diseases related to proteins in ChEMBL interactions
OMIM (75)
| OMIM | preferred title | UniProt |
|---|---|---|
| #300438 | 17-beta-hydroxysteroid dehydrogenase x deficiency |
Q99714
|
| #219080 | Acth-independent macronodular adrenal hyperplasia; aimah |
P63092
|
| #202300 | Adrenocortical carcinoma, hereditary; adcc |
P04637
|
| #300068 | Androgen insensitivity syndrome; ais |
P10275
|
| #312300 | Androgen insensitivity, partial; pais |
P10275
|
| #614740 | Basal cell carcinoma, susceptibility to, 7; bcc7 |
P04637
|
| #614490 | Blood group, junior system; jr |
Q9UNQ0
|
| %606641 | Body mass index; bmi |
P37231
|
| #115200 | Cardiomyopathy, dilated, 1a; cmd1a |
P02545
|
| #212112 | Cardiomyopathy, dilated, with hypergonadotropic hypogonadism |
P02545
|
| #609338 | Carotid intimal medial thickness 1 |
P37231
|
| #605588 | Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 |
P02545
|
| #114500 | Colorectal cancer; crc |
P18054
P84022 |
| #119900 | Digital clubbing, isolated congenital |
P15428
|
| #609535 | Drug metabolism, poor, cyp2c19-related |
P33261
|
| #237500 | Dubin-johnson syndrome; djs |
Q92887
|
| #181350 | Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 |
P02545
|
| #133239 | Esophageal cancer |
P04637
P18054 |
| #615363 | Estrogen resistance; estrr |
P03372
|
| #600274 | Frontotemporal dementia; ftd |
P10636
|
| #608013 | Gaucher disease, perinatal lethal |
P04062
|
| #230800 | Gaucher disease, type i |
P04062
|
| #230900 | Gaucher disease, type ii |
P04062
|
| #231000 | Gaucher disease, type iii |
P04062
|
| #231005 | Gaucher disease, type iiic |
P04062
|
| #137800 | Glioma susceptibility 1; glm1 |
P37231
|
| #232300 | Glycogen storage disease ii |
P10253
|
| #605130 | Hairy elbows, short stature, facial dysmorphism, and developmental delay |
Q03164
|
| #610140 | Heart-hand syndrome, slovenian type |
P02545
|
| #176670 | Hutchinson-gilford progeria syndrome; hgps |
P02545
|
| #143860 | Hyperchlorhidrosis, isolated |
O43570
|
| #145000 | Hyperparathyroidism 1; hrpt1 |
O00255
|
| #603373 | Hyperthyroidism, familial gestational |
P16473
|
| #609152 | Hyperthyroidism, nonautoimmune |
P16473
|
| #259100 | Hypertrophic osteoarthropathy, primary, autosomal recessive, 1; phoar1 |
P15428
|
| #275200 | Hypothyroidism, congenital, nongoitrous, 1; chng1 |
P16473
|
| #612244 | Inflammatory bowel disease 13; ibd13 |
P08183
|
| #151623 | Li-fraumeni syndrome 1; lfs1 |
P04637
|
| #151660 | Lipodystrophy, familial partial, type 2; fpld2 |
P02545
|
| #604367 | Lipodystrophy, familial partial, type 3; fpld3 |
P37231
|
| #613795 | Loeys-dietz syndrome, type 3; lds3 |
P84022
|
| #211980 | Lung cancer |
P04637
|
| #248370 | Mandibuloacral dysplasia with type a lipodystrophy; mada |
P02545
|
| #174800 | Mccune-albright syndrome; mas |
P63092
|
| #300705 | Mental retardation, x-linked 17; mrx17 |
Q99714
|
| #300220 | Mental retardation, x-linked, syndromic 10; mrxs10 |
Q99714
|
| #131100 | Multiple endocrine neoplasia, type i; men1 |
O00255
|
| #613205 | Muscular dystrophy, congenital, lmna-related |
P02545
|
| #159001 | Muscular dystrophy, limb-girdle, type 1b; lgmd1b |
P02545
|
| #607948 | Mycobacterium tuberculosis, susceptibility to |
P11473
|
| #257200 | Niemann-pick disease, type a |
P17405
|
| #607616 | Niemann-pick disease, type b |
P17405
|
| #601665 | Obesity |
P37231
|
| #166350 | Osseous heteroplasia, progressive; poh |
P63092
|
| #259730 | Osteopetrosis, autosomal recessive 3; optb3 |
P00918
|
| #260500 | Papilloma of choroid plexus; cpp |
P04637
|
| #168600 | Parkinson disease, late-onset; pd |
P04062
|
| #260540 | Parkinson-dementia syndrome |
P10636
|
| #172700 | Pick disease of brain |
P10636
|
| #102200 | Pituitary adenoma, growth hormone-secreting |
P63092
|
| #103580 | Pseudohypoparathyroidism, type ia; php1a |
P63092
|
| #603233 | Pseudohypoparathyroidism, type ib; php1b |
P63092
|
| #612462 | Pseudohypoparathyroidism, type ic; php1c |
P63092
|
| #275210 | Restrictive dermopathy, lethal |
P02545
|
| #600852 | Retinitis pigmentosa 17; rp17 |
P22748
|
| #313200 | Spinal and bulbar muscular atrophy, x-linked 1; smax1 |
P10275
|
| #607250 | Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy; scan1 |
Q9NUW8
|
| #275355 | Squamous cell carcinoma, head and neck; hnscc |
P04637
|
| #601104 | Supranuclear palsy, progressive, 1; psnp1 |
P10636
|
| #188570 | Thyroid hormone resistance, generalized, autosomal dominant; grth |
P10828
|
| #274300 | Thyroid hormone resistance, generalized, autosomal recessive; grth |
P10828
|
| #145650 | Thyroid hormone resistance, selective pituitary; prth |
P10828
|
| #138900 | Uric acid concentration, serum, quantitative trait locus 1; uaqtl1 |
Q9UNQ0
|
| #277440 | Vitamin d-dependent rickets, type 2a; vddr2a |
P11473
|
| #278750 | Xeroderma pigmentosum, variant type; xpv |
Q9Y253
|
KEGG DISEASE (91)
| KEGG | disease name | UniProt |
|---|---|---|
| H00033 | Adrenal carcinoma |
O00255
(related)
P04637 (related) |
| H00034 | Carcinoid |
O00255
(related)
|
| H00045 | Malignant islet cell carcinoma |
O00255
(related)
|
| H00246 | Primary hyperparathyroidism |
O00255
(related)
|
| H01102 | Pituitary adenomas |
O00255
(related)
|
| H01302 | Hyperchlorhidrosis isolated (HCHLH) |
O43570
(related)
|
| H00021 | Renal cell carcinoma |
O43570
(marker)
P04637 (marker) Q16790 (marker) |
| H00241 | Combined proximal and distal renal tubular acidosis (RTA type 3) |
P00918
(related)
|
| H00436 | Osteopetrosis |
P00918
(related)
|
| H00264 | Charcot-Marie-Tooth disease (CMT) |
P02545
(related)
|
| H00294 | Dilated cardiomyopathy (DCM) |
P02545
(related)
|
| H00420 | Familial partial lipodystrophy (FPL) |
P02545
(related)
P37231 (related) |
| H00563 | Emery-Dreifuss muscular dystrophy |
P02545
(related)
|
| H00590 | Congenital muscular dystrophies (CMD/MDC) |
P02545
(related)
|
| H00593 | Limb-girdle muscular dystrophy (LGMD) |
P02545
(related)
|
| H00601 | Hutchinson-Gilford progeria syndrome |
P02545
(related)
|
| H00663 | Restrictive dermopathy |
P02545
(related)
|
| H00665 | Mandibuloacral dysplasia |
P02545
(related)
|
| H01216 | Left ventricular noncompaction (LVNC) |
P02545
(related)
|
| H00026 | Endometrial Cancer |
P03372
(marker)
P04637 (related) |
| H00066 | Lewy body dementia (LBD) |
P04062
(related)
|
| H00126 | Gaucher disease |
P04062
(related)
|
| H00426 | Defects in the degradation of ganglioside |
P04062
(related)
|
| H00810 | Progressive myoclonic epilepsy (PME) |
P04062
(related)
|
| H00004 | Chronic myeloid leukemia (CML) |
P04637
(related)
|
| H00005 | Chronic lymphocytic leukemia (CLL) |
P04637
(related)
|
| H00006 | Hairy-cell leukemia |
P04637
(related)
|
| H00008 | Burkitt lymphoma |
P04637
(related)
|
| H00009 | Adult T-cell leukemia |
P04637
(related)
|
| H00010 | Multiple myeloma |
P04637
(related)
|
| H00013 | Small cell lung cancer |
P04637
(related)
|
| H00014 | Non-small cell lung cancer |
P04637
(related)
|
| H00015 | Malignant pleural mesothelioma |
P04637
(related)
|
| H00016 | Oral cancer |
P04637
(related)
P04637 (marker) |
| H00017 | Esophageal cancer |
P04637
(related)
P04637 (marker) |
| H00018 | Gastric cancer |
P04637
(related)
|
| H00019 | Pancreatic cancer |
P04637
(related)
P04637 (marker) |
| H00020 | Colorectal cancer |
P04637
(related)
P04637 (marker) |
| H00022 | Bladder cancer |
P04637
(related)
|
| H00025 | Penile cancer |
P04637
(related)
P04637 (marker) |
| H00027 | Ovarian cancer |
P04637
(related)
|
| H00028 | Choriocarcinoma |
P04637
(related)
|
| H00029 | Vulvar cancer |
P04637
(related)
|
| H00031 | Breast cancer |
P04637
(related)
|
| H00032 | Thyroid cancer |
P04637
(related)
P37231 (related) |
| H00036 | Osteosarcoma |
P04637
(related)
P08684 (marker) |
| H00038 | Malignant melanoma |
P04637
(related)
|
| H00039 | Basal cell carcinoma |
P04637
(related)
|
| H00040 | Squamous cell carcinoma |
P04637
(related)
|
| H00041 | Kaposi's sarcoma |
P04637
(related)
|
| H00042 | Glioma |
P04637
(related)
P04637 (marker) |
| H00044 | Cancer of the anal canal |
P04637
(related)
|
| H00046 | Cholangiocarcinoma |
P04637
(related)
|
| H00047 | Gallbladder cancer |
P04637
(related)
|
| H00048 | Hepatocellular carcinoma |
P04637
(related)
|
| H00055 | Laryngeal cancer |
P04637
(related)
P04637 (marker) |
| H00881 | Li-Fraumeni syndrome |
P04637
(related)
|
| H01007 | Choroid plexus papilloma |
P04637
(related)
|
| H00069 | Glycogen storage diseases (GSD) |
P10253
(related)
|
| H00024 | Prostate cancer |
P10275
(related)
|
| H00062 | Spinal and bulbar muscular atrophy (SBMA) |
P10275
(related)
|
| H00608 | 46,XY disorders of sex development (Disorders in androgen synthesis or action) |
P10275
(related)
|
| H00609 | 46,XY disorders of sex development (Other) |
P10275
(related)
|
| H00058 | Amyotrophic lateral sclerosis (ALS) |
P10636
(related)
|
| H00077 | Progressive supranuclear palsy (PSP) |
P10636
(related)
|
| H00078 | Frontotemporal lobar degeneration (FTLD) |
P10636
(related)
|
| H00249 | Thyroid hormone resistance syndrome |
P10828
(related)
|
| H00342 | Tuberculosis |
P11473
(related)
|
| H00784 | Localized autosomal recessive hypotrichosis |
P11473
(related)
|
| H01143 | Vitamin D-dependent rickets |
P11473
(related)
|
| H01205 | Coumarin resistance |
P11712
(related)
|
| H00457 | Primary hypertrophic osteoarthropathy (PHO) |
P15428
(related)
|
| H01246 | Isolated congenital nail clubbing (ICNC) |
P15428
(related)
|
| H00250 | Congenital nongoitrous hypothyroidism (CHNG) |
P16473
(related)
|
| H01269 | Congenital hyperthyroidism |
P16473
(related)
|
| H00137 | Niemann-Pick disease (NPD) typeA and B |
P17405
(related)
|
| H00424 | Defects in the degradation of sphingomyelin |
P17405
(related)
|
| H00527 | Retinitis pigmentosa (RP) |
P22748
(related)
|
| H01171 | Poor drug metabolism (PM) |
P33261
(related)
|
| H00409 | Type II diabetes mellitus |
P37231
(related)
|
| H00244 | Pseudohypoparathyroidism |
P63092
(related)
|
| H00441 | Progressive osseous heteroplasia (POH) |
P63092
(related)
|
| H00501 | Fibrous dysplasia, polyostotic |
P63092
(related)
|
| H00001 | Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) |
Q03164
(related)
Q03164 (marker) |
| H00002 | Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia) |
Q03164
(related)
|
| H00208 | Hyperbilirubinemia |
Q92887
(related)
|
| H00480 | Non-syndromic X-linked mental retardation |
Q99714
(related)
|
| H00658 | Syndromic X-linked mental retardation |
Q99714
(related)
|
| H00925 | 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency |
Q99714
(related)
|
| H00063 | Spinocerebellar ataxia (SCA) |
Q9NUW8
(related)
|
| H00403 | Disorders of nucleotide excision repair |
Q9Y253
(related)
|
Diseases related to CTD interactions
6 disease from interactions of metabolites
| MeSH disease | OMIM | compound | disease name | evidence type |
reference
pmid |
|---|---|---|---|---|---|
| D058186 | C440975 | Acute Kidney Injury |
therapeutic
|
10454517
|
|
| D056486 | C440975 | Drug-Induced Liver Injury |
therapeutic
|
17696131
22229868 |
|
| D006943 | C440975 | Hyperglycemia |
therapeutic
|
22137898
|
|
| D007674 | C440975 | Kidney Diseases |
therapeutic
|
23070905
|
|
| D008106 | C440975 | Liver Cirrhosis, Experimental |
therapeutic
|
16169303
|
|
| D008175 | C440975 | Lung Neoplasms |
therapeutic
|
16788158
|